A wide range of approaches exist for treating aggressive nonmelanoma skin cancers, including surgery, radiation therapy (RT), cytotoxic chemotherapy, systemic immunotherapy, and active surveillance. Selecting an appropriate therapeutic approach
Search Results
Management of Patients With Aggressive Nonmelanoma Skin Cancers
Presented by: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop
Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas
Presented by: Ann S. LaCasce and Ariela Noy
, for example, and stage I disease is curable by surgery or radiation therapy. “Indolent lymphomas are generally incurable when they present with disseminated disease, but patients can live for years or even decades,” said Dr. Noy, who noted that
The Impact of Electromagnetic Navigational Bronchoscopy on a Multidisciplinary Thoracic Oncology Program
Craig Brown, Sharon Ben-Or, Paul Walker, and Mark Bowling
the main foci of therapy is stereotactic body radiation therapy (SBRT), which uses fiducial markers to track the movement of the lung during the respiratory cycle, minimizing the damage to normal tissue as high doses of radiation are applied to the
Pelvic Bone Sarcomas: Controversies and Treatment Options
Carol D. Morris
conditions frequently treated with radiation therapy (RT). Within the pelvis, the ilium is the most common location for osteosarcoma, followed by the acetabulum then the ischium. Tumors frequently involve more than one part of the pelvis, and iliac tumors
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, and Susan Darlow
phase III CONKO-001 trial, in which 368 patients without prior chemotherapy or radiation therapy (RT) were randomly assigned to adjuvant gemcitabine versus observation following macroscopically complete resection, an intent-to-treat analysis of the data
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
local disease with surgery, radiation therapy, or both, and systemic treatment with chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The need for and selection of various local or systemic therapies are based on several
Pediatric Hodgkin Lymphoma, Version 3.2021
Jamie E. Flerlage, Susan M. Hiniker, Saro Armenian, Ellen C. Benya, Adam J. Bobbey, Vivian Chang, Stacy Cooper, Don W. Coulter, Branko Cuglievan, Bradford S. Hoppe, Leidy Isenalumhe, Kara Kelly, Leslie Kersun, Adam J. Lamble, Nicole A. Larrier, Jeffrey Magee, Kwadwo Oduro, Martha Pacheco, Anita P. Price, Kenneth B. Roberts, Christine M. Smith, Aliyah R. Sohani, Erin M. Trovillion, Emily Walling, Ana C. Xavier, Jennifer L. Burns, and Mallory Campbell
application of criteria to determine the need for radiation therapy. PET interpretation is very challenging given the high sensitivity without specificity. In cases of PET positivity where sites of disease are not consistent with usual presentation of HL or
Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas Farrington, Celestia S. Higano, Eric Mark Horwitz, Philip W. Kantoff, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Stan Rosenfeld, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Przemyslaw Twardowski, Patrick C. Walsh, Maria Ho, and Dorothy A. Shead
alternative to immediate treatment with radical prostatectomy or radiation for slow-growing tumors. For patients with high-risk localized tumors or locally advanced disease, external beam radiation therapy (EBRT) with androgen deprivation therapy (ADT) has
Management of Central Nervous System Tumors
Thomas Kaley and Louis B. Nabors
brain metastases.” “The incidence of brain metastases is thought to be increasing with new more effective systemic cancer treatment,” he added. Older trials have shown that surgery plus radiation therapy improves outcome for patients with brain
BPI19-008: Racial Disparities in Breast Cancer Treatment Based on NCCN Quality Guidelines
Surbhi Agarwal, Ruta Rao, and David Ansell
Background: NCCN quality measures for breast cancer include (1) radiation therapy administered within 1 year of diagnosis for women under age 70 receiving breast-conserving surgery; (2) chemotherapy considered in 4 months of diagnosis for women
